Berzosertib is a Small Molecule owned by Merck, and is involved in 22 clinical trials, of which 6 were completed, and 16 are ongoing.

Berzosertib is an inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- and radiotherapy. 

The revenue for Berzosertib is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Berzosertib NPV Report.

Berzosertib was originated by Vertex Pharmaceuticals and is currently owned by Merck.

Berzosertib Overview

Berzosertib (VX-970) is under development for the treatment of solid tumors including squamous non-small cell lung cancer, osteosarcoma, leiomyosarcoma, metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, head and neck squamous cell carcinoma and small cell lung cancer, neuroendocrine tumors, peritoneal cancer, fallopian tube cancer, metastatic ovarian cancer, adenocarcinoma or squamous cell carcinoma of the oesophagus, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), middle east respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). The drug candidate is administered through intravenous route. VX-970 is an ATR kinase inhibitor. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of urothelial carcinoma of pelvic and bladder, ureter cancer, colorectal cancer, non-metastatic and metastatic triple negative breast cancer (estrogen receptor, progesterone receptor, HER2 negative), pancreatic cancer and gastroesophageal junction adenocarcinoma.

Merck Overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.

Quick View – Berzosertib

Report Segments
  • Innovator
Drug Name
  • Berzosertib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.